Tetrathiomolybdate inhibits mitochondrial complex IV and mediates degradation of hypoxia-inducible factor-1α in cancer cells
Kyu Kwang Kim(Brown University), Richard G. Moore(University of Rochester Medical Center)
Cited by 62
Related Papers
Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C
|BMC Cancer|2012|40
Role of trypsin and protease-activated receptor-2 in ovarian cancer
|PLoS ONE|2020|40
Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers
|Scientific Reports|2015|22
Efficacy of a Non-Hypercalcemic Vitamin-D2 Derived Anti-Cancer Agent (MT19c) and Inhibition of Fatty Acid Synthesis in an Ovarian Cancer Xenograft Model
|PLoS ONE|2012|20
Development of Potent Forchlorfenuron Analogs and Their Cytotoxic Effect in Cancer Cell Lines
|Scientific Reports|2020|20